Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 5Thoracic 1Sarcoma 1Other solid neoplasm 1Head & Neck 1Dermatologic 1CNS 1

Conditions

Sarcoma 317Gastrointestinal Stromal Tumors 108Neoplasms 105Breast Neoplasms 92Melanoma 81Ovarian Neoplasms 79Neoplasm Metastasis 74Carcinoma, Non-Small-Cell Lung 74Colorectal Neoplasms 70Osteosarcoma 61Stomach Neoplasms 59Pancreatic Neoplasms 55Bone Neoplasms 55Prostatic Neoplasms 51Head and Neck Neoplasms 48Glioblastoma 48Sarcoma, Ewing 47Lung Neoplasms 45Esophageal Neoplasms 42Squamous Cell Carcinoma of Head and Neck 41Carcinoma, Renal Cell 40Uterine Cervical Neoplasms 39Sarcoma, Kaposi 38Lymphoma 37Urinary Bladder Neoplasms 36Sarcoma, Synovial 36Recurrence 35Dendritic Cell Sarcoma, Interdigitating 34Lymphoma, Non-Hodgkin 33Endometrial Neoplasms 33

Interventions

LY2940680 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Pituitary Diseases × Sarcoma × Clear all
NCT05199584 2026-03-05

A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations

Endeavor Biomedicines, Inc.

Phase 2 Completed
20 enrolled
CNSDermatologicEndocrineHead & NeckOther solid neoplasmSarcomaThoracic

Uveal Melanoma, Glioma, Adenoma, Islet Cell, Laryngeal Diseases, Medulloblastoma, Melanoma, Mesothelioma, Neuroblastoma, Pituitary Diseases, Retinoblastoma, Rhabdomyosarcoma, Sarcoma, Osteosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡